title: Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1).
abstract: BACKGROUND
  The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed.
  
  
  METHODS
  We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC overexpressing HER2/neu at 3 + level by IHC treated with the anti-HER2/neu antibody-drug-conjugate (ADC) trastuzumab-emtansine (TDM-1-Kadcyla-Genentech/Roche). She experienced a remarkable clinical response to TDM-1 with a complete resolution of a large metastatic, radiation/chemotherapy resistant tumor deposit in her abdominal wall muscle confirmed by multiple CAT scans and a prolonged systemic control of her disease.
  
  
  CONCLUSIONS
  TDM-1 may represent a novel treatment option for recurrent/metastatic HER2/neu-positive USC patients refractory to salvage-treatment.
authors.affiliation: Department of Obstetrics & Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
authors.forename: Alessandro D
authors.initials: AD
authors.lastname: Santin
authors.affiliation: Department of Obstetrics & Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
authors.forename: Stefania
authors.initials: S
authors.lastname: Bellone
authors.affiliation: Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, United States.
authors.forename: Natalia
authors.initials: N
authors.lastname: Buza
authors.affiliation: Department of Obstetrics & Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
authors.forename: Peter E
authors.initials: PE
authors.lastname: Schwartz
keywords: HER2/neu; Trastuzumab-emtansine; Uterine serous carcinoma